ArticleThe Lancet. Oncology2024

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.

Antonio D'Alessio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.